LAUNXP BIOMEDICAL CO., LTD.

As of June 30, 2026, LAUNXP BIOMEDICAL CO., LTD. carries a market capitalization of 1.13B, placing it among publicly traded companies globally. Its enterprise value stands at 686.26M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, LAUNXP BIOMEDICAL CO., LTD. has 70.70M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, LAUNXP BIOMEDICAL CO., LTD. maintains a current ratio of 3.45, meaning it holds 3.5x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

As of the close on October 22, 2026, LAUNXP BIOMEDICAL CO., LTD.'s stock has declined approximately 40.59% over the past 52 weeks. The 50-day moving average sits at 14.17, while the 200-day moving average is 18.33.

As of June 30, 2026, LAUNXP BIOMEDICAL CO., LTD. holds 455.28M in cash and equivalents against 6.87M in total debt, resulting in a net debt position of -355.28M. Total book value stands at 369.05M, with working capital of 335.76M providing operational flexibility.